0001104659-20-010943 4 1 20200131 20200205 20200205 Hoffman Michael B 0001290208 4 34 001-39202 20576287 (203) 413-2200 1 GREENWICH OFFICE PARK GREENWICH CT 06831 Annovis Bio, Inc. 0001477845 2834 262540421 DE 1231 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 QR Pharma, Inc. 20091202 4 1 a4.xml 4 X0306 4 2020-01-31 0 0001477845 Annovis Bio, Inc. ANVS 0001290208 Hoffman Michael B C/O ANNOVIS BIO, INC. 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 1 0 1 0 Common Stock 2020-01-31 4 P 0 33333 6.00 A 47619 D Common Stock 2020-01-31 4 C 0 158730 A 206349 D Common Stock 2020-01-31 4 C 0 1137942 A 1344291 D Common Stock 2020-01-31 4 C 0 55884 4.80 A 1400175 D Series A-1 Preferred Stock 2020-01-31 4 C 0 222222 0 D Common Stock 158730 0 D Series A Preferred Stock 2020-01-31 4 C 0 1593118 0 D Common Stock 1137942 0 D Convertible Note 2020-01-31 4 C 0 55884 4.80 D Common Stock 55884 0 D The reporting person acquired these shares in the initial public offering ("IPO") of Annovis Bio, Inc. ("Annovis"). Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. Each share of Series A Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price). /s/ Michael Hoffman 2020-02-04